Vision
Hans Group will provide innovative top-class medical equipment
and biomedical supplies until a patient is fully satisfied.
No. 1 Global
No. 1 in the world
(artificial breast implants, lifting suture)
100 Countries
Exports to more than 100 countries
(R&D investment in the field of new medical treatments and technology)
500 Billion
Achieved the sales of 500 billion KRW
(growth rate gradually increasing)
Hans Achievements
Approved by the U.S. FDA, MFDS, CE, AATB, etc. for its excellent technology and reliable safety
Make
Innovations
1999 - 2002
Established Hans Biomed Co. Ltd.
Selected as "World Top-Class Product Company"
Constructed a tissue engineering research lab
2003 - 2005
Registered human tissue implants to FDA
Acquired permission for establishing Korea's first human tissue bank from MFDS
2008 - 2009
Artificial breast approved by CE
Listed on KOSDAQ, the first in the industry
2012
Approved by AATB (American Association of Tissue Banks)
Demineralized Bone Matrix (DBM) approved by the U.S. FDA 510K
Steady
Development
2013 - 2015
Extended Daejeon Tissue Engineering Research Center
MINT LIFT approved by MFDS
MINT LIFT approved by the U.S. FDA
Artificial breast by MFDS
2015 - 2019
BellaGel Micro approved in Korea
The smart factory for artificial breasts in the world
Artificial breasts approved by CNMPA
DBM approved by CNMPA
MINT LIFT approved by CE
Embolic material for vascular disease treatment approved in Korea
2020 - 2022
Preclinical test of stem cell project for diabetes treatment approved
Preclinical test of embolic material for liver cancer treatment approved